Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CLINICAL CORNER: Spectranetics’ DCB, Pixium’s Bionic Vision, Endologix EVAS, Biocartis’ Liquid Biopsy

This article was originally published in Clinica

Executive Summary

You may also be interested in...



Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold

The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.

TCT Round-Up: The Next Generation Of Drug-Eluting Stents, Drug-Coated Balloon Featured At Washington Conference

One of the world’s largest showcases for new interventional cardiology technology, the 2016 Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific sessions, were held Oct. 29-Nov. 2 in Washington, DC. This year’s edition of TCT featured many presentations on new drug-eluting coronary stent technologies, as well as drug-coated balloons for peripheral interventions.

Pixium's IRIS II CE Mark Stokes Retinal Implant Rivalry

Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.

Topics

Latest News
UsernamePublicRestriction

Register

MT103475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel